美沙拉嗪联合小檗碱对远端溃疡性结肠炎的疗效及对TNF-α、IL-17和IL-23水平影响  

Effect of mesalazine combined with berberine on the levels of TNF-α,IL-17 and IL-23 in patients with distal ulcerative colitis

作　　者：陈怡 贾杰 郑娟红 CHEN Yi;JIA Jie;ZHENG Juanhong(Department of Gastroenterology,Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine in Zhejiang Province,Wenzhou 325000,China)

机构地区：[1]浙江省温州市中西医结合医院消化内科,浙江温州325000

出　　处：《中国现代医生》2021年第22期46-49,共4页China Modern Doctor

基　　金：浙江省医药卫生科技计划项目(2017KY629)。

摘　　要：目的探讨美沙拉嗪联合小檗碱对远端溃疡性结肠炎的临床疗效及对TNF-α、IL-17和IL-23水平影响。方法选取我院消化内科自2016年12月至2019年12月收治的116例远端溃疡性结肠炎患者,将其随机分为对照组与观察组,每组各58例,在常规治疗的基础上对照组加用美沙拉嗪,观察组加用美沙拉嗪联用盐酸小檗碱保留灌肠,两组均连续治疗21 d,考察两组的临床疗效、症状缓解时间、炎症因子水平变化及不良反应等。结果观察组临床总有效率(94.8%)与对照组(75.9%)比较,差异有统计学意义(P<0.05);观察组腹痛、腹泻和黏液脓血便缓解时间分别为(3.2±0.6)d、(3.5±0.8)d、(4.7±1.1)d,与对照组腹痛、腹泻和黏液脓血便缓解时间[(5.6±1.3)d、(6.1±1.7)d、(6.4±1.8)d]比较,差异有统计学意义(P<0.05);观察组炎症因子TNF-α、IL-17和IL-23水平分别为(15.68±3.26)ng/mL、(226.29±58.46)pg/mL、(324.85±39.24)pg/mL,对照组分别为(24.17±4.61)ng/mL、(325.69±65.27)pg/mL、(431.42±43.77)pg/mL,两组比较,差异均有统计学意义(P<0.05);观察组不良反应发生率为17.3%,与对照组的19.0%比较,差异无统计学意义(P>0.05)。结论美沙拉嗪联合小檗碱对远端溃疡性结肠炎,可显著改善临床症状,提高临床疗效,有较好的临床借鉴意义。Objective To investigate the clinical effect of mesalazine combined with berberine on the levels of TNF-α,IL-17 and IL-23 in patients with distal ulcerative colitis.Methods A total of 116 patients with distal ulcerative colitis admitted to the department of gastroenterology of our hospital from December 2016 to December 2019 were selected as the research objects and randomly divided into the observation group(n=58)and the control group(n=58).On the basis of conventional treatment,the control group was treated additionally with mesalazine,while the observation group was treated additionally with mesalazine combined with berberine hydrochloride retention enema.The two groups were treated for 21 days,and the clinical efficacy,symptom relief time,inflammatory factor level and adverse reactions of the two groups were investigated.Results The total effective rates were 94.8% in the observation group and 75.9% in the control group,and the difference between the two groups was statistically significant(P<0.05).The relief time of abdominal pain,diarrhea and mucous pus and blood stool was(3.2±0.6)d,(3.5±0.8)d and(4.7±1.1)d in the observation group,and(5.6±1.3)d,(6.1±1.7)d and(6.4±1.8)d in the control group,respectively,and the difference between the two groups was statistically significant(P<0.05).The levels of inflammatory factors TNF-α,IL-17 and IL-23 were(15.68±3.26)ng/mL,(226.29±58.46)pg/mL and(324.85±39.24)pg/mL in the observation group and(24.17±4.61)ng/mL,(325.69±65.27)pg/mL and(431.42±43.77)pg/mL in the control group,respectively,and the differences between the two groups were statistically significant(P<0.05).The incidences of adverse reactions were 17.3% in the observation group and 19.0%in the control group,showing no statistically significant difference(P>0.05).Conclusion Mesalazine combined with berberine in the treatment of distal ulcerative colitis can significantly improve the clinical symptoms and the clinical efficacy,which has a good clinical reference significance.

关 键 词：结肠炎 美沙拉嗪 小檗碱 灌肠 

分 类 号：R978.1[医药卫生—药品]